Straits Times Index
3,394.21 +17.02 (+0.50%) Nikkei
27,382.56 +19.81 (+0.07%) Hang Seng
22,688.90 +122.12 (+0.54%) FTSE 100
7,765.15 +4.04 (+0.05%) BTC-USD
23,159.79 +61.00 (+0.26%) CMC Crypto 200
526.66 +9.65 (+1.87%)
Coherus BioSciences, Inc. (CHRS)
After hours:
| Previous close | 8.35 |
| Open | 8.32 |
| Bid | 8.02 x 1200 |
| Ask | 9.29 x 800 |
| Day's range | 8.31 - 8.76 |
| 52-week range | 5.58 - 14.11 |
| Volume | |
| Avg. volume | 1,282,872 |
| Market cap | 648.668M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.75 |
| Earnings date | 15 Feb 2023 - 20 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.75 |
- Zacks
Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -81.13% and 20.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Here's Why Coherus BioSciences (CHRS) Looks Ripe for Bottom Fishing
Coherus BioSciences (CHRS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- Zacks
Wall Street Analysts Think Coherus BioSciences (CHRS) Could Surge 47%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 47.3% in Coherus BioSciences (CHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
